Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol [Internet]. 2015;1:505–27. https://doi.org/10.1001/jamaoncol.2015.0735

Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepato-Biliary-Pancreatic Sci [Internet]. 2016;23:149–57. https://doi.org/10.1002/jhbp.314.

Article  Google Scholar 

Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol [Internet]. 2011;41:40–51. https://doi.org/10.1093/jjco/hyq167.

Article  PubMed  Google Scholar 

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med [Internet]. 2010;362:1273–81. https://doi.org/10.1056/NEJMoa0908721.

Article  CAS  PubMed  Google Scholar 

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer [Internet]. 2010;103:469–74. https://doi.org/10.1038/sj.bjc.6605779.

Article  CAS  PubMed  Google Scholar 

Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol [Internet]. 2019;30:1950–8. https://doi.org/10.1093/annonc/mdz402.

Article  CAS  PubMed  Google Scholar 

Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). Journal of Hepato-Biliary-Pancreatic Sciences [Internet]. 2022;1–9. Available from: https://doi.org/10.1002/jhbp.1219

Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol [Internet]. 2015;75:293–300. https://doi.org/10.1007/s00280-014-2648-9.

Article  CAS  PubMed  Google Scholar 

Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition [Internet]. 2021. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33259690

Oh Do-Youn, Ruth He Aiwu, Qin Shukui, Chen Li-Tzong, Okusaka Takuji, Vogel Arndt, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence [Internet]. 2022;1:EVIDoa2200015. Available from: https://doi.org/10.1056/EVIDoa2200015

Benson AB, D’Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN Guidelines® insights: biliary tract cancers, Version 2.2023. J Natl Compr Canc Netw [Internet]. 2023;21:694–704. https://doi.org/10.6004/jnccn.2023.0035.

Article  CAS  PubMed  Google Scholar 

ESMO. Clinical practice guideline – biliary tract cancer [Internet]. [cited 2023 Jul 14]. Available from: https://www.esmo.org/guidelines/guidelines-by-topic/gastrointestinal-cancers/biliary-tract-cancer

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2023;401:1853–65. https://doi.org/10.1016/S0140-6736(23)00727-4.

Article  PubMed  Google Scholar 

Kashiwa M, Matsushita R. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer. Int J Clin Pharm [Internet]. 2023;45:875–83. https://doi.org/10.1007/s11096-023-01580-2.

Article  CAS  PubMed  Google Scholar 

Ye Z-M, Xu Z, Li H, Li Q. Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer. Front Public Health [Internet]. 2023;11:1046424. https://doi.org/10.3389/fpubh.2023.1046424.

Article  PubMed  Google Scholar 

Zhao Q, Xie R, Zhong W, Liu W, Chen T, Qiu X, et al. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost Eff Resour Alloc [Internet]. 2023;21:19. https://doi.org/10.1186/s12962-023-00429-9.

Article  PubMed  Google Scholar 

Zheng Z, Fang L, Cai H. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China. BMC Cancer [Internet]. 2023;23:823. https://doi.org/10.1186/s12885-023-11255-w.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Liu K, Zhu H. Immune checkpoint inhibitor for patients with advanced biliary tract cancer: a cost-effectiveness analysis. Liver Int [Internet]. 2023; Available from: https://doi.org/10.1111/liv.15699

Center for Outcomes Research and Economic Evaluation for Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council version 3.0. 2022; Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf

Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology [Internet]. 2012;12. Available from: https://doi.org/10.1186/1471-2288-12-9

Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol [Internet]. 2011;11:61. https://doi.org/10.1186/1471-2288-11-61.

Article  PubMed  Google Scholar 

Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health [Internet]. 2020;23:918–27. https://doi.org/10.1016/j.jval.2020.03.010.

Article  PubMed  Google Scholar 

Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan. J Gastrointest Cancer [Internet]. 2017;48:326–32. https://doi.org/10.1007/s12029-016-9885-6.

Article  PubMed  Google Scholar 

CEA registry [Internet]. Available from: https://cevr.tuftsmedicalcenter.org/databases/cea-registry

Conversion rates - Exchange rates - OECD Data [Internet]. theOECD. .Available from: https://data.oecd.org/conversion/exchange-rates.htm

Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012 [in Japanese]. Nihon Jinzo Gakkai shi [Internet]. 2012;54:1034–191. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23387281

Reimbursement schedule of social insurance. Tokyo, Japan- Ministry of Health Labor and Welfare; 2022. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411_00037.html

National health insurance drug price. Standard. Tokyo, Japan: Jiho Inc; 2022.

Ministry of health, labour and welfare, diagnostic procedure classification (DPC) electronic score table [Internet]. [cited 2023 Jul 19]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000198757_00004.html

Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, et al. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: Post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol [Internet]. 2018;48:410–6. https://doi.org/10.1093/jjco/hyy030.

Article  PubMed  Google Scholar 

Kato K, Fukuda H. Comparative economic evaluation of home-based and hospital-based palliative care for terminal cancer patients. Geriatr Gerontol Int [Internet]. 2017;17:2247–54. https://doi.org/10.1111/ggi.12977.

Article  PubMed  Google Scholar 

Shindo Y, Nagano H, Kanai M, Kobayashi S, Wada H, Sakai D, et al. Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncol Rep [Internet]. 2023;49. Available from: https://doi.org/10.3892/or.2023.8478

Tikhonova IA, Huxley N, Snowsill T, Crathorne L, Varley-Campbell J, Napier M, et al. Economic analysis of first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England. PharmacoEconomics [Internet]. 2018;36:837–51. https://doi.org/10.1007/S40273-018-0630-9.

Article  PubMed  Google Scholar 

Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int [Internet]. 2023;43:1803–12. https://doi.org/10.1111/liv.15641.

Article  CAS  PubMed  Google Scholar